The FDA released a communication on Monday stating that it “remains concerned” about the potentially higher risk of venal thromboembolism (a type of blood clot) in women taking Yaz, Yasmin, and other fourth-generation birth control pills containing drospirenone, according to USA Today. Yaz blood clots have been an ongoing concern for many users, and the FDA is conducting a study to investigate the risk when compared to those of older contraceptives.
Studies suggest that these drugs present double or triple the risk of venal thromboembolism.
Preliminary findings suggest that there is a 50% higher chance of developing a birth control blood clot on Yaz and other fourth-generation pills than with other oral contraceptives. The overall risk for an individual remains small (10 per 10,000 users, as opposed to 6 per 10,000 users), but the study has not ended, and the risk-to-benefit ratio of these drugs still needs to be assessed. Additionally, other studies suggest a stronger correlation, with two published in the British Medical Journal claiming that these drugs present double or triple the risk of venal thromboembolism.
Women should not stop taking their current birth control without speaking with their doctor first, but any woman who has been victim to a Yaz blood clot should contact an attorney immediately after seeking medical attention. The more these incidents are reported, the better the FDA can assess the true dangers of the drugs. The agency will reconvene in December, when the full results of the study will be released.
If you are taking a birth control pill and you experience leg pain, chest pain, or sudden shortness of breath, contact a doctor immediately. If you need legal counsel, fill out the form on the right for a free consultation with our experienced product liability attorneys.